These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 30937719)

  • 1. Role of Liver Stiffness Measurement in Predicting HCC Occurrence in Direct-Acting Antivirals Setting: A Real-Life Experience.
    Rinaldi L; Guarino M; Perrella A; Pafundi PC; Valente G; Fontanella L; Nevola R; Guerrera B; Iuliano N; Imparato M; Trabucco A; Sasso FC; Morisco F; Ascione A; Piai G; Adinolfi LE
    Dig Dis Sci; 2019 Oct; 64(10):3013-3019. PubMed ID: 30937719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis.
    You MW; Kim KW; Shim JJ; Pyo J
    J Gastroenterol Hepatol; 2021 Mar; 36(3):601-608. PubMed ID: 32875681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
    Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals.
    Tamaki N; Higuchi M; Kurosaki M; Kirino S; Osawa L; Watakabe K; Wang W; Okada M; Shimizu T; Takaura K; Takada H; Kaneko S; Yasui Y; Tsuchiya K; Nakanishi H; Itakura J; Takahashi Y; Enomoto N; Izumi N
    J Viral Hepat; 2019 Jul; 26(7):893-899. PubMed ID: 30974045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.
    Rinaldi L; Perrella A; Guarino M; De Luca M; Piai G; Coppola N; Pafundi PC; Ciardiello F; Fasano M; Martinelli E; Valente G; Nevola R; Monari C; Miglioresi L; Guerrera B; Berretta M; Sasso FC; Morisco F; Izzi A; Adinolfi LE
    J Transl Med; 2019 Aug; 17(1):292. PubMed ID: 31462268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
    Pons M; Rodríguez-Tajes S; Esteban JI; Mariño Z; Vargas V; Lens S; Buti M; Augustin S; Forns X; Mínguez B; Genescà J
    J Hepatol; 2020 Mar; 72(3):472-480. PubMed ID: 31629779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.
    Alonso López S; Manzano ML; Gea F; Gutiérrez ML; Ahumada AM; Devesa MJ; Olveira A; Polo BA; Márquez L; Fernández I; Cobo JCR; Rayón L; Riado D; Izquierdo S; Usón C; Real Y; Rincón D; Fernández-Rodríguez CM; Bañares R
    Hepatology; 2020 Dec; 72(6):1924-1934. PubMed ID: 33022803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients.
    Wang HM; Hung CH; Lu SN; Chen CH; Lee CM; Hu TH; Wang JH
    Liver Int; 2013 May; 33(5):756-61. PubMed ID: 23405889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography.
    Masuzaki R; Tateishi R; Yoshida H; Yoshida H; Sato S; Kato N; Kanai F; Sugioka Y; Ikeda H; Shiina S; Kawabe T; Omata M
    J Clin Gastroenterol; 2008 Aug; 42(7):839-43. PubMed ID: 18668703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver stiffness measurements in chronic hepatitis C: Treatment evaluation and risk assessment.
    Nakagomi R; Tateishi R; Masuzaki R; Soroida Y; Iwai T; Kondo M; Fujiwara N; Sato M; Minami T; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Kondo Y; Tanaka Y; Otsuka M; Kato N; Moriya K; Ikeda H; Koike K
    J Gastroenterol Hepatol; 2019 May; 34(5):921-928. PubMed ID: 30393960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
    PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
    Degasperi E; Galmozzi E; Pelusi S; D'Ambrosio R; Soffredini R; Borghi M; Perbellini R; Facchetti F; Iavarone M; Sangiovanni A; Valenti L; Lampertico P
    Hepatology; 2020 Dec; 72(6):1912-1923. PubMed ID: 32762045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis.
    Wang JH; Chuah SK; Lu SN; Hung CH; Kuo CM; Tai WC; Chiou SS
    Liver Int; 2014 Oct; 34(9):1340-8. PubMed ID: 24620731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Stiffness Measurement and Risk Prediction of Hepatocellular Carcinoma After HCV Eradication in Veterans With Cirrhosis.
    John BV; Dang Y; Kaplan DE; Jou JH; Taddei TH; Spector SA; Martin P; Bastaich DR; Chao HH; Dahman B
    Clin Gastroenterol Hepatol; 2024 Apr; 22(4):778-788.e7. PubMed ID: 38061410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of liver stiffness predicts complications in patients with HCV related cirrhosis treated with direct-acting antivirals.
    Nicoletti A; Ainora ME; Cintoni M; Garcovich M; Funaro B; Pecere S; De Siena M; Santopaolo F; Ponziani FR; Riccardi L; Grieco A; Pompili M; Gasbarrini A; Zocco MA
    Dig Liver Dis; 2023 Nov; 55(11):1472-1479. PubMed ID: 37142455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcirrhotic liver stiffness by FibroScan correlates with lower risk of hepatocellular carcinoma in patients with HBV-related cirrhosis.
    Jeon MY; Lee HW; Kim SU; Heo JY; Han S; Kim BK; Park JY; Kim DY; Ahn SH; Han KH
    Hepatol Int; 2017 May; 11(3):268-276. PubMed ID: 28224351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIGH VALUES OF LIVER STIFFNESS PLAY AN IMPORTANT ROLE IN STRATIFYING THE RISK OF HEPATOCELLULAR CARCINOMA IN CIRRHOTIC HEPATITIS C PATIENTS.
    Reinoso-Pereira GL; Paranaguá-Vezozzo DC; Mazo DF; França JID; Ono SK; Carrilho FJ
    Arq Gastroenterol; 2022; 59(2):204-211. PubMed ID: 35830030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Predictability of Non-invasive Tools for Hepatocellular Carcinoma in Treated Chronic Hepatitis C Patients.
    Liu YC; Cheng YT; Chen YC; Hsieh YC; Jeng WJ; Lin CY; Chien RN; Tai DI; Sheen IS
    Dig Dis Sci; 2023 Jan; 68(1):323-332. PubMed ID: 35895234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.